The Asia-Pacific CDMO market is on track to grow from $42B in 2024 to over $68B by 2027, driven by India's PLI scheme, China's dual-track API strategy, and Singapore's life sciences hub expansion.
India's Resurgence
Indian CDMOs have invested significantly in US FDA and EU GMP compliance upgrades. Companies like Divi's Laboratories and Dr. Reddy's are capturing increasing share of complex molecule synthesis.